Jeffrey M. Dayno
CIK 1615993 · PRESIDENT, CEO · last filed 2026-01-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
HRMY price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1050
WAYNE, PA 19087
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HRMY | PRESIDENT, CEO | 13,000 | $37.16 | $483.0K | -$5.43M | 16 | 2026-01-26 |
| Zyla Life Sciences (EGLT) Delisted | Chief Medical Officer | 18,212 | — | — | -$57.9K | 14 | 2017-06-12 |
Recent Filings · Page 3 of 4
32 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-01-04 | Zyla Life Sciences (EGLT) Delisted | Sell (S) | −536 | -$4.2K | EDGAR |
| 2016-12-08 | Zyla Life Sciences (EGLT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-10-03 | Zyla Life Sciences (EGLT) Delisted | Sell (S) | −536 | -$4.1K | EDGAR |
| 2016-07-05 | Zyla Life Sciences (EGLT) Delisted | Sell (S) | −536 | -$2.5K | EDGAR |
| 2016-04-04 | Zyla Life Sciences (EGLT) Delisted | Sell (S) | −536 | -$3.6K | EDGAR |
| 2016-01-05 | Zyla Life Sciences (EGLT) Delisted | Sell (S) | −536 | -$5.6K | EDGAR |
| 2015-11-24 | Zyla Life Sciences (EGLT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-10-28 | Zyla Life Sciences (EGLT) Delisted | Sell (S) | −536 | -$4.8K | EDGAR |
| 2015-07-02 | Zyla Life Sciences (EGLT) Delisted | Sell (S) | −536 | -$8.2K | EDGAR |
| 2015-02-03 | Zyla Life Sciences (EGLT) Delisted | Sell (S) | −2,500 | -$22.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.